{
  "demographics": {
    "age": {
      "30-39": 0.15,
      "40-49": 0.25,
      "50-59": 0.35,
      "60+": 0.25
    },
    "gender": {
      "male": 0.65,
      "female": 0.35
    },
    "state_distribution": {
      "CA": 0.12,
      "TX": 0.08,
      "NY": 0.07,
      "FL": 0.06,
      "other": 0.67
    },
    "practice_setting": {
      "academic": 0.35,
      "community": 0.55,
      "other": 0.10
    }
  },
  "practice_context": {
    "urban_vs_rural": {
      "urban": 0.80,
      "rural": 0.20
    },
    "patient_mix": {
      "medicare": 0.55,
      "medicaid": 0.15,
      "commercial": 0.30
    },
    "copd_patient_volume": {
      "low": 0.20,
      "medium": 0.50,
      "high": 0.30
    }
  },
  "treatment_patterns": {
    "guideline_adherence": {
      "strict": 0.40,
      "moderate": 0.40,
      "low": 0.20
    },
    "preferred_initial_therapy": {
      "LAMA": 0.30,
      "LABA": 0.20,
      "LAMA+LABA": 0.35,
      "ICS+LABA": 0.15
    },
    "biologic_adoption": {
      "early_adopter": 0.10,
      "mainstream": 0.30,
      "late_or_never": 0.60
    }
  },
  "variation_drivers": {
    "generation": {
      "younger (<45)": "higher adoption of biologics, digital tools",
      "older (â‰¥45)": "slower adoption, more pragmatic prescribing"
    },
    "academic_vs_community": {
      "academic": "higher GOLD adherence, trial participation",
      "community": "resource-constrained, pragmatic adjustments"
    },
    "urban_vs_rural": {
      "urban": "access to rehab, biologics",
      "rural": "limited rehab, more ICS use"
    }
  }
}
